SkyePharma To Jettison Its Injectables Business
This article was originally published in The Pink Sheet Daily
Executive Summary
The firm will use proceeds from the divestiture to develop its oral and pulmonary products, including the pipeline asthma therapy Flutiform.
You may also be interested in...
Innovata And SkyePharma Discussing Merger
U.K.-based firms both have expertise in pulmonary delivery systems.
Tarceva Pancreatic Cancer Indication Turned Down In The EU
Roche will consider requesting a re-examination of the negative decision by the Committee for Medicinal Products for Human Use.
Teva To Investigate High-Dose Copaxone
A Phase III trial will compare 40 mg/day glatiramer to the 20 mg/day approved dose.